December 23, 2005 – AstraZeneca added to its product portfolio by buying KuDos Pharma, a privately owned UK biotech, for $210 million; Wyeth has joined with Progenics to develop a therapy for constipation and post-operative bowel dysfunction; Alexza Pharma filed its registration statement for its IPO; EntreMed will buy privately held Miikana Therapeutics for $21.2 million in stock; Par Pharma will buy eight generic products from Teva and Ivax, which they must divest before completing their consolidation; Roche granted a Tamiflu license to Hetero Drugs of India; Novovax booked its second cash payment from Esprit Pharma for Estrasorb; and Amylin Pharma has selected a site to produce its extended release formulation of diabetes drug Byetta. In a quiet pre-holiday session, the Centient Biotech 200™ closed 10.5 points lower at 4009.73, a loss of .26%. More details...
